SK4012000A3 - Method for purification of antithrombin iii - Google Patents

Method for purification of antithrombin iii Download PDF

Info

Publication number: SK4012000A3
Authority: SK; Slovakia
Prior art keywords: iii; complex; heparin; heparinoid; atiii
Prior art date: 1997-09-19

Application number

SK401-2000A

Other languages

English (en)

Slovak (sk)

Inventor

Yendra Linnau

Ernst Hetzl

H Peter Matthiessen

Silvia Neppl

Wolfgang Schonhofer

Hans-Peter Schwarz

Original Assignee

Baxter Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-09-19

Filing date

1998-09-17

Publication date

2000-10-09

1998-09-17 Application filed by Baxter Ag filed Critical Baxter Ag

2000-10-09 Publication of SK4012000A3 publication Critical patent/SK4012000A3/sk

Links

108090000935 Antithrombin III Proteins 0.000 title claims abstract description 24
238000000034 method Methods 0.000 title claims abstract description 24
102000004411 Antithrombin III Human genes 0.000 title claims abstract description 8
229960005348 antithrombin iii Drugs 0.000 title claims abstract description 8
238000000746 purification Methods 0.000 title abstract description 5
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 40
229960002897 heparin Drugs 0.000 claims abstract description 40
229920000669 heparin Polymers 0.000 claims abstract description 40
229920001499 Heparinoid Polymers 0.000 claims abstract description 21
239000002554 heparinoid Substances 0.000 claims abstract description 21
238000010828 elution Methods 0.000 claims abstract description 11
238000005349 anion exchange Methods 0.000 claims abstract description 8
239000000463 material Substances 0.000 claims abstract description 7
239000007858 starting material Substances 0.000 claims abstract description 5
102100022977 Antithrombin-III Human genes 0.000 claims description 16
241000700605 Viruses Species 0.000 claims description 6
239000000872 buffer Substances 0.000 claims description 6
230000002779 inactivation Effects 0.000 claims description 6
238000010438 heat treatment Methods 0.000 claims description 4
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
230000000087 stabilizing effect Effects 0.000 claims description 3
101100135609 Arabidopsis thaliana PAP10 gene Proteins 0.000 claims description 2
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 claims description 2
229910052921 ammonium sulfate Inorganic materials 0.000 claims description 2
235000011130 ammonium sulphate Nutrition 0.000 claims description 2
238000011097 chromatography purification Methods 0.000 claims description 2
239000012678 infectious agent Substances 0.000 claims description 2
239000012149 elution buffer Substances 0.000 claims 1
238000003776 cleavage reaction Methods 0.000 description 12
230000007017 scission Effects 0.000 description 12
150000001450 anions Chemical class 0.000 description 11
-1 for example Substances 0.000 description 10
238000001179 sorption measurement Methods 0.000 description 7
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
239000007853 buffer solution Substances 0.000 description 5
239000000243 solution Substances 0.000 description 5
229920002307 Dextran Polymers 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
239000000499 gel Substances 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 3
229920002271 DEAE-Sepharose Polymers 0.000 description 3
102000007327 Protamines Human genes 0.000 description 3
108010007568 Protamines Proteins 0.000 description 3
229920005654 Sephadex Polymers 0.000 description 3
239000012507 Sephadex™ Substances 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
238000003795 desorption Methods 0.000 description 3
229940025770 heparinoids Drugs 0.000 description 3
238000004255 ion exchange chromatography Methods 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
229940048914 protamine Drugs 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229920000936 Agarose Polymers 0.000 description 2
201000005657 Antithrombin III deficiency Diseases 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
239000012564 Q sepharose fast flow resin Substances 0.000 description 2
239000012614 Q-Sepharose Substances 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
238000005571 anion exchange chromatography Methods 0.000 description 2
239000003957 anion exchange resin Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
238000001914 filtration Methods 0.000 description 2
208000033666 hereditary antithrombin deficiency Diseases 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
239000002245 particle Substances 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000000126 substance Substances 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
YYPNJNDODFVZLE-UHFFFAOYSA-N 3-methylbut-2-enoic acid Chemical compound CC(C)=CC(O)=O YYPNJNDODFVZLE-UHFFFAOYSA-N 0.000 description 1
102000015790 Asparaginase Human genes 0.000 description 1
108010024976 Asparaginase Proteins 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
QYGLUJXJUQWIKB-UHFFFAOYSA-N CC(=CC(=O)OCC(CO)(CO)CO)C Chemical compound CC(=CC(=O)OCC(CO)(CO)CO)C QYGLUJXJUQWIKB-UHFFFAOYSA-N 0.000 description 1
206010053567 Coagulopathies Diseases 0.000 description 1
108010032608 Cohn fraction IV Proteins 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
208000005189 Embolism Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
208000028782 Hereditary disease Diseases 0.000 description 1
208000026350 Inborn Genetic disease Diseases 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
239000004793 Polystyrene Substances 0.000 description 1
108010094028 Prothrombin Proteins 0.000 description 1
102100027378 Prothrombin Human genes 0.000 description 1
206010040047 Sepsis Diseases 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
MZVQCMJNVPIDEA-UHFFFAOYSA-N [CH2]CN(CC)CC Chemical group [CH2]CN(CC)CC MZVQCMJNVPIDEA-UHFFFAOYSA-N 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
239000001166 ammonium sulphate Substances 0.000 description 1
229960003272 asparaginase Drugs 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-M asparaginate Chemical compound [O-]C(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-M 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
230000035602 clotting Effects 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
238000007334 copolymerization reaction Methods 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
230000000694 effects Effects 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 1
230000014509 gene expression Effects 0.000 description 1
VOZRXNHHFUQHIL-UHFFFAOYSA-N glycidyl methacrylate Chemical compound CC(=C)C(=O)OCC1CO1 VOZRXNHHFUQHIL-UHFFFAOYSA-N 0.000 description 1
210000003709 heart valve Anatomy 0.000 description 1
239000000017 hydrogel Substances 0.000 description 1
230000005660 hydrophilic surface Effects 0.000 description 1
230000005661 hydrophobic surface Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
208000012442 inherited thrombophilia Diseases 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
244000000010 microbial pathogen Species 0.000 description 1
238000001728 nano-filtration Methods 0.000 description 1
229920002114 octoxynol-9 Polymers 0.000 description 1
238000009928 pasteurization Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000011197 physicochemical method Methods 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920000193 polymethacrylate Polymers 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000053 polysorbate 80 Polymers 0.000 description 1
229920002223 polystyrene Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
229940039716 prothrombin Drugs 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8128—Antithrombin III
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Life Sciences & Earth Sciences (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SK401-2000A 1997-09-19 1998-09-17 Method for purification of antithrombin iii SK4012000A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
AT0159497A AT405739B (de)	1997-09-19	1997-09-19	Verfahren zur reinigung von antithrombin iii
PCT/AT1998/000223 WO1999015562A1 (fr)	1997-09-19	1998-09-17	Procede de purification de l'antithrombine iii

Publications (1)

Publication Number	Publication Date
SK4012000A3 true SK4012000A3 (en)	2000-10-09

Family

ID=3516803

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK401-2000A SK4012000A3 (en)	1997-09-19	1998-09-17	Method for purification of antithrombin iii

Country Status (11)

Country	Link
US (1)	US6395880B1 (fr)
EP (1)	EP1015491A1 (fr)
JP (1)	JP2001517679A (fr)
AT (1)	AT405739B (fr)
AU (1)	AU742861B2 (fr)
BR (1)	BR9812229A (fr)
CA (1)	CA2303924A1 (fr)
HU (1)	HUP0003671A1 (fr)
NO (1)	NO20001414L (fr)
SK (1)	SK4012000A3 (fr)
WO (1)	WO1999015562A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070123251A1 (en) *	1996-10-23	2007-05-31	Riparius Ventures, Llc	Remote internet telephony device
US8546548B2 (en)	2009-05-27	2013-10-01	Baxter International Inc.	Method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
PT2477603E (pt)	2009-09-17	2016-06-16	Baxalta Inc	Co-formulação estável de hialuronidase e imunoglobulina e métodos para a sua utilização
DE102016009442A1 (de) *	2016-08-03	2018-02-08	Fresenius Medical Care Deutschland Gmbh	Verfahren zur Überwachung des Bicarbonat-Gehalts und des Natrium-Gehalts einer Dialyselösung
ES2906118T3 (es)	2016-12-22	2022-04-13	Km Biologics Co Ltd	Método cromatográfico para recolectar factor VII de coagulación sanguínea con alto rendimiento
BR102017005783A2 (pt) *	2017-03-21	2018-10-02	Fund Butantan	processo de obtenção de esculptina e seus fragmentos, esculptina recombinante e seus usos
AU2024351533A1 (en)	2023-09-26	2026-03-19	Takeda Pharmaceutical Company Limited	IMMUNOGLOBULIN FORMULATIONS DEPLETED IN IgA

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE392038B (sv)	1971-09-08	1977-03-14	Kabi Ab	Forfarande for isolering av antitrombin ur blod eller blodprodukter
US4286056A (en) *	1980-01-28	1981-08-25	Baxter Travenol Laboratories, Inc.	Method for making therapeutic enzyme compositions
AT379310B (de) *	1983-05-20	1985-12-27	Immuno Ag	Verfahren zur herstellung eines antithrombin iii-heparin- bzw. antithrombin iii-heparinoidkonzentrates
US4540573A (en)	1983-07-14	1985-09-10	New York Blood Center, Inc.	Undenatured virus-free biologically active protein derivatives
AT389815B (de)	1984-03-09	1990-02-12	Immuno Ag	Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4749783A (en)	1986-07-11	1988-06-07	Miles Laboratories, Inc.	Viral inactivation and purification of active proteins
AT402891B (de)	1991-06-20	1997-09-25	Immuno Ag	Verfahren zur herstellung eines inaktivierten blutproduktes
US5319072A (en) *	1992-01-10	1994-06-07	Alpha Therapeutic Corporation	Human antithrombin-III preparation
EP0674531A1 (fr)	1992-12-16	1995-10-04	IMMUNO Aktiengesellschaft	Procede de preparation de compositions biologiques exemptes de virus
DE4434538C2 (de)	1993-10-06	2000-08-10	Immuno Ag	Verfahren zur Virusinaktivierung in Gegenwart eines Polyethers und eines chaotropen Agens

1997
- 1997-09-19 AT AT0159497A patent/AT405739B/de not_active IP Right Cessation
1998
- 1998-09-17 HU HU0003671A patent/HUP0003671A1/hu unknown
- 1998-09-17 WO PCT/AT1998/000223 patent/WO1999015562A1/fr not_active Ceased
- 1998-09-17 JP JP2000512865A patent/JP2001517679A/ja active Pending
- 1998-09-17 BR BR9812229-0A patent/BR9812229A/pt not_active Application Discontinuation
- 1998-09-17 US US09/509,052 patent/US6395880B1/en not_active Expired - Fee Related
- 1998-09-17 AU AU92448/98A patent/AU742861B2/en not_active Ceased
- 1998-09-17 CA CA002303924A patent/CA2303924A1/fr not_active Abandoned
- 1998-09-17 EP EP98944885A patent/EP1015491A1/fr not_active Withdrawn
- 1998-09-17 SK SK401-2000A patent/SK4012000A3/sk unknown
2000
- 2000-03-17 NO NO20001414A patent/NO20001414L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
EP1015491A1 (fr)	2000-07-05
AU9244898A (en)	1999-04-12
NO20001414L (no)	2000-05-18
JP2001517679A (ja)	2001-10-09
AT405739B (de)	1999-11-25
CA2303924A1 (fr)	1999-04-01
ATA159497A (de)	1999-03-15
US6395880B1 (en)	2002-05-28
WO1999015562A1 (fr)	1999-04-01
BR9812229A (pt)	2000-07-18
AU742861B2 (en)	2002-01-17
NO20001414D0 (no)	2000-03-17
HUP0003671A1 (hu)	2001-02-28

Publication	Publication Date	Title
EP0893450B1 (fr)	2004-05-19	Procédé chromatographique de purification d'IgG avec un haut rendement et rendant les virus inactifs
EP0363126B2 (fr)	2002-03-06	Méthode pour la purification de protéines dépendantes de la vitamine K
US20110237781A1 (en)	2011-09-29	Method of preparing alpha-1 proteinase inhibitor
US6955917B2 (en)	2005-10-18	Chromatographic method for high yield purification and viral inactivation of antibodies
CZ328795A3 (en)	1996-07-17	Concentrate of immunoglobulins g for therapeutical use and process for preparing thereof
JPH0764750B2 (ja)	1995-07-12	アルフア−１−プロテイナ−ゼ阻害剤の製造方法
EP0617049B1 (fr)	1999-09-01	Procédé pour l'isolation des facteurs IX, X, et II hautement purifiés de complexe de prothrombine ou de plasma humain
PL164754B1 (pl)	1994-10-31	Sposób wytwarzania koncentratu kompleksu czynnika krzepniecia krwi VIII z czynnikiemWlllebranda PL PL PL PL PL
CA2059979C (fr)	2003-04-15	Complexe contenant le facteur de coagulation ix
US7041798B1 (en)	2006-05-09	Method for the chromatographic fractionation of plasma or serum, preparations, so obtained, and their use
US6395880B1 (en)	2002-05-28	Method for purification of antithrombin III using an anion exchanger
HU219828B (hu)	2001-08-28	Eljárás K-vitamin-függő proteinek izolálására és tisztítására
WO1999018130A1 (fr)	1999-04-15	Procede de purification d'immunoglobulines
Burnouf et al.	1998	Application of bioaffinity technology in therapeutic extracorporeal plasmapheresis and large-scale fractionation of human plasma
US5744586A (en)	1998-04-28	Manufacturing process for the production of purified transferrin
SK284215B6 (sk)	2004-11-03	Spôsob výroby frakcie s inaktivovanými vírusmi obsahujúcej faktor VIII
CZ2000983A3 (cs)	2000-10-11	Způsob čištění antithrombinu III
EP0815873B1 (fr)	2002-09-11	Stabilisation sélective de protéines par liaison à un ligand d'affinité pendant l'inactivation virale
MXPA00002620A (en)	2001-05-07	Method for purification of antithrombin iii
WO2000034453A1 (fr)	2000-06-15	PURIFICATION DE L'INHIBITEUR DE LA PROTEINASE α1
AU729682C (en)	2001-09-20	Manufacturing process for the production of purified transferrin
KR830001822B1 (ko)	1983-09-12	유로 키나제의 제조방법